RAPPORT THERAPEUTICS INC (RAPP) Fundamental Analysis & Valuation

NASDAQ:RAPP • US75383L1026

Current stock price

27.84 USD
-1.16 (-4%)
At close:
27.84 USD
0 (0%)
After Hours:

This RAPP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RAPP Profitability Analysis

1.1 Basic Checks

  • In the past year RAPP has reported negative net income.
  • In the past year RAPP has reported a negative cash flow from operations.
RAPP Yearly Net Income VS EBIT VS OCF VS FCFRAPP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • RAPP has a Return On Assets of -21.76%. This is in the better half of the industry: RAPP outperforms 60.10% of its industry peers.
  • RAPP's Return On Equity of -23.00% is fine compared to the rest of the industry. RAPP outperforms 67.36% of its industry peers.
Industry RankSector Rank
ROA -21.76%
ROE -23%
ROIC N/A
ROA(3y)-23%
ROA(5y)N/A
ROE(3y)-24.44%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RAPP Yearly ROA, ROE, ROICRAPP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -10 -20 -30 -40 -50

1.3 Margins

  • RAPP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RAPP Yearly Profit, Operating, Gross MarginsRAPP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. RAPP Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for RAPP has been increased compared to 1 year ago.
  • There is no outstanding debt for RAPP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RAPP Yearly Shares OutstandingRAPP Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 10M 20M 30M 40M
RAPP Yearly Total Debt VS Total AssetsRAPP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • RAPP has an Altman-Z score of 28.41. This indicates that RAPP is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 28.41, RAPP belongs to the top of the industry, outperforming 93.78% of the companies in the same industry.
  • There is no outstanding debt for RAPP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 28.41
ROIC/WACCN/A
WACCN/A
RAPP Yearly LT Debt VS Equity VS FCFRAPP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • RAPP has a Current Ratio of 26.17. This indicates that RAPP is financially healthy and has no problem in meeting its short term obligations.
  • RAPP has a better Current ratio (26.17) than 95.85% of its industry peers.
  • RAPP has a Quick Ratio of 26.17. This indicates that RAPP is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 26.17, RAPP belongs to the top of the industry, outperforming 95.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 26.17
Quick Ratio 26.17
RAPP Yearly Current Assets VS Current LiabilitesRAPP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. RAPP Growth Analysis

3.1 Past

  • The earnings per share for RAPP have decreased strongly by -29.51% in the last year.
EPS 1Y (TTM)-29.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 0.50% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25.68%
EPS Next 2Y-19.4%
EPS Next 3Y-10.18%
EPS Next 5Y0.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RAPP Yearly Revenue VS EstimatesRAPP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
RAPP Yearly EPS VS EstimatesRAPP Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. RAPP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RAPP. In the last year negative earnings were reported.
  • Also next year RAPP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RAPP Price Earnings VS Forward Price EarningsRAPP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RAPP Per share dataRAPP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as RAPP's earnings are expected to decrease with -10.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.4%
EPS Next 3Y-10.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RAPP Dividend Analysis

5.1 Amount

  • No dividends for RAPP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RAPP Fundamentals: All Metrics, Ratios and Statistics

RAPPORT THERAPEUTICS INC

NASDAQ:RAPP (3/27/2026, 8:00:01 PM)

After market: 27.84 0 (0%)

27.84

-1.16 (-4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-10
Earnings (Next)05-06
Inst Owners106.55%
Inst Owner Change0.52%
Ins Owners4.64%
Ins Owner Change-1.04%
Market Cap1.33B
Revenue(TTM)N/A
Net Income(TTM)-111.48M
Analysts85
Price Target53.27 (91.34%)
Short Float %7.85%
Short Ratio10.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.06%
Min EPS beat(2)-4.11%
Max EPS beat(2)10.23%
EPS beat(4)3
Avg EPS beat(4)7.5%
Min EPS beat(4)-4.11%
Max EPS beat(4)12.28%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.95%
PT rev (3m)-0.05%
EPS NQ rev (1m)11.72%
EPS NQ rev (3m)13.5%
EPS NY rev (1m)0.2%
EPS NY rev (3m)0.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.75
P/tB 2.75
EV/EBITDA N/A
EPS(TTM)-2.86
EYN/A
EPS(NY)-3.59
Fwd EYN/A
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.83
OCFYN/A
SpS0
BVpS10.14
TBVpS10.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.76%
ROE -23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-23%
ROA(5y)N/A
ROE(3y)-24.44%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.57%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.17
Quick Ratio 26.17
Altman-Z 28.41
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)602.65%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.32%
EPS Next Y-25.68%
EPS Next 2Y-19.4%
EPS Next 3Y-10.18%
EPS Next 5Y0.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-50.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.19%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-31.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.93%
OCF growth 3YN/A
OCF growth 5YN/A

RAPPORT THERAPEUTICS INC / RAPP Fundamental Analysis FAQ

What is the fundamental rating for RAPP stock?

ChartMill assigns a fundamental rating of 3 / 10 to RAPP.


What is the valuation status for RAPP stock?

ChartMill assigns a valuation rating of 0 / 10 to RAPPORT THERAPEUTICS INC (RAPP). This can be considered as Overvalued.


What is the profitability of RAPP stock?

RAPPORT THERAPEUTICS INC (RAPP) has a profitability rating of 1 / 10.


What is the financial health of RAPPORT THERAPEUTICS INC (RAPP) stock?

The financial health rating of RAPPORT THERAPEUTICS INC (RAPP) is 8 / 10.